KRAS and colorectal carcinoma: Our study confirmed a high percentage of KRAS missense somatic mutations (38.2%) in CRC samples, of which 94.5% of mutations were located in exon 2 and 5.5% in exon 3 of the KRAS gene, as evidenced in the literature.